Loading quotes...

Forecast

The analysts' average price target is €33.27 (+289.12%). The median is €28.52 (+233.57%).

Buy	1
Hold	0
Sell	0

News Go to news feed

Adlai Nortye treats first patient in phase‑I study with AN4035

Adlai Nortye has treated the first patient with the antibody–drug conjugate AN4035 in Australia, thereby starting a global phase‑I study for CEACAM5‑enriched, RAS‑dependent solid tumors. The FDA issued a study‑may‑proceed decision for the IND, allowing the trial to be expanded to the US, and an application to the National Medical Products Administration in China is planned. AN4035 delivers a pan‑RAS(ON) inhibitor and will be evaluated in the study for safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy as monotherapy and in combination with cetuximab. Adlai Nortye aims to report full phase‑Ia data in the second half of 2027; preclinically, AN4035 showed cytotoxic activity and tumor regression in CEACAM5‑positive models. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Adlai Nortye Ltd. American Depositary Shares has already paid €0.0606 in dividends. The last payout was in June 2025.

Financials

In the last quarter, Adlai Nortye Ltd. American Depositary Shares had revenue of €6.43m and net profit of -€2.34m

(EUR)	June 2026	YoY
Revenue	6.43m	-
Gross profit	6.43m	-
Net profit	-2.34m	69.94%
EBITDA	-2.36m	70.20%

Fundamentals

Metric	Value
Market capitalization	€451.76m
Number of shares	53.08m
52-week high/low	€15.37 - €0.78
Dividends	No
Beta	1.16
P/E ratio	-4.88
PEG ratio	-0.07
P/B ratio	0.71
P/S ratio	25.76

Company profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.